App-Quantinova.ai

SUN-348 Cabozantinib in Advanced Adrenocortical Carcinoma: Rationale and Protocol of Two Phase II Clinical Trials

Matthias Kroiss - Endocrine Society (ENDO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Adrenal carcinoma

Cabozantinib

EXTH-46. ALISERTIB POTENTIATES THE EFFECT OF CABOZANTINIB AND VANDETANIB AGAINST GLIOBLASTOMA CELLS

Brian Williams - Society for Neuro-Oncology (SNO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Glioblastoma

Cabozantinib

MP58-17 THE CONTRIBUTION OF HGF-MET-MMP1 SIGNALING IN BLADDER CANCER INVASION, AND MET INHIBITOR AS A POTENTIAL THERAPEUTIC OPTION FOR INVASIVE BLADDER CANCER

Tomoya Fukawa - American Urological Association (AUA) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Cabozantinib

Management of treatment-related toxicity caused by multi kinase inhibitors administered due to advanced thyroid carcinoma

Jolanta Krajewska - European Congress of Endocrinology (ECE) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Cabozantinib

Phase II trial of cabozantinib in patients with carcinoid and pancreatic neuroendocrine tumors (pNET).

Jennifer A. Chan - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

Cabozantinib

Evolution of circulating tumor DNA (ctDNA) profile from first-line (1L) to second-line (2L) therapy in metastatic renal cell carcinoma (mRCC).

Sumanta K. Pal - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Cabozantinib

Outcomes based on age in the phase 3 METEOR trial of cabozantinib (cabo) versus everolimus (eve) in patients with advanced renal cell carcinoma (RCC).

Frede Donskov - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Cabozantinib

18F-FDG-PET/CT imaging to assess response to treatment with cabozantinib at 4 weeks versus 8 weeks of therapy in patients (pts) with metastatic urothelial carcinoma (mUC).

Nicole N. Davarpanah - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Cabozantinib

Cabozantinib for the treatment of patients with metastatic variant histology renal cell carcinoma (vhRCC): A retrospective study.

Matthew T. Campbell - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Cabozantinib

Cabozantinib plus androgen deprivation therapy in patients with androgen-dependent metastatic prostate cancer.

Paul Gettys Corn - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Cabozantinib

Assessing bone response to cabozantinib in patients (pts) with metastatic urothelial carcinoma (mUC) using 18F-Sodium Fluoride (NaF) PET/CT.

Jeffrey Lin - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Cabozantinib

Cabozantinib (C) exposure-response (ER) modeling of safety endpoints in patients (pts) with renal cell carcinoma (RCC) in the phase III METEOR study.

Steven Lacy - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Cabozantinib

Analysis of overall survival (OS) based on tumor target lesion change in the phase 3 METEOR trial of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC).

Sumanta K. Pal - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Cabozantinib

A phase I study of cabozantinib plus nivolumab (CaboNivo) and ipilimumab (CaboNivoIpi) in patients (pts) with refractory metastatic urothelial carcinoma (mUC) and other genitourinary (GU) tumors.

Andrea B. Apolo - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Cabozantinib

Whole-exome sequencing of matched germline and plasma cell-free DNA portrays the somatic mutation landscape of refractory metastatic colorectal cancer and identifies mutated KDR/VEGFR2 as new cause of therapy resistance

R.A.Toledo - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Cabozantinib

Cabozantinib in patients with advanced penile squamous cell carcinoma (PSCC): the open-label, single-arm, single-center, phase 2, CaboPen trial

A.Necchi - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Cabozantinib

Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase III CELESTIAL trial.

Ghassan K. Abou-Alfa - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Cabozantinib

Quality-adjusted life years assessment using cabozantinib for patients with advanced hepatocellular carcinoma (aHCC) in the CELESTIAL trial.

Ghassan K. Abou-Alfa - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

Cabozantinib

Integrated population pharmacokinetic (PopPK) modeling of cabozantinib (C) in patients (pts) with various cancer types including hepatocellular carcinoma (HCC).

Linh Thuy Nguyen - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

Cabozantinib

Real world eligibility for cabozantinib (C), regorafenib (Reg), and ramucirumab (Ram) in hepatocellular carcinoma (HCC) patients after sorafenib (S).

Andrea S. Fung - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

Cabozantinib

Filters

366 Abstracts